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with laterocervical and submandibu-
lar lymphadenitis. Total lymph node 
excision was performed with a good 
outcome for all patients except 1, who 
required additional treatment with an-
timicrobial drugs because the infected 
lymph node was incompletely excised 
(4). Additionally, a systemic M. bohe-
micum infection associated with im-
munodeﬁ  ciency was reported recently 
(10). Treatment recommendations for 
nontuberculous mycobacterial lymph-
adenitis are outlined in discussions of 
individual nontuberculous mycobacte-
rium species. Guidelines for localized 
lymphadenitis caused by any non-
tuberculous mycobacterium species 
recommend complete surgical exci-
sion of the involved lymph nodes (8). 
Additional antimicrobial drug therapy 
is recommended only for patients for 
whom removal was incomplete (8). 
Our patient who received combina-
tion antimicrobial drug treatment im-
proved, with no relapse.
In summary we report 4 cases of 
M. bohemicum from Austria, a coun-
try with 8 million inhabitants. Because 
these cases were observed in a rela-
tively small country, infections with 
M. bohemicum may be more common 
than previously thought. More such 
cases may be discovered as a result 
of improved microbiologic diagnostic 
techniques. We believe that M. bohe-
micum should be listed among the spe-
cies that induce nontuberculous myco-
bacterial infections.
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Pertussis 
Surveillance in 
Private Pediatric 
Practices, France, 
2002–2006 
To the Editor: In France, pertus-
sis epidemiology has been extensively 
studied since 1993. Immunization 
of children with a highly efﬁ  cacious 
pertussis whole-cell (Pw) vaccine 
(Sanoﬁ   Pasteur MSD, Lyon, France) 
for 40 years (since 1966) has reduced 
the incidence of pertussis. It has been 
demonstrated that infectious or vacci-
nal immunity to pertussis wanes with 
time and that pertussis is no longer a 
pediatric disease (1–5). Transmission 
now occurs predominantly from ado-
lescents and adults to unvaccinated 
newborns.
From 1966 through 1995, pri-
mary vaccination against pertussis 
was administered to children at 3, 4, 
and 5 months of age, and a booster 
was given at ≈2 years of age. Since 
1995, primary vaccination has been 
administered at 2, 3, and 4 months of 
age, and a booster is given at 16–18 
months of age. Duration of protection 
of children immunized with Pw vac-
cine at these schedules is estimated to 
be ≈7–9 years (1,5). 
In response to the problem of 
waning immunity, a second pertussis 
booster immunization at 11–13 years 
of age was introduced in 1998 (6). De-
velopment of pertussis acellular (Pa) 
vaccines has enabled administration of 
this booster immunization. The French 
hospital network surveillance system 
(Renacoq) was established in 1996 
to monitor severe pertussis in infants 
and the effect of late booster immuni-
zations. A cyclic disease pattern was 
observed; peaks were noted for 1993, 
1997, 2000, and 2005. However, the 
last peak had a low amplitude; since 
then a diminution in the proportion of 
siblings who transmitted the infection 
to young infants was observed (2). 
These results could have been caused 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 7, July 2008  1159 LETTERS
by adolescent booster immunizations.
We evaluated whether the dura-
tion of immunity induced by Pw vac-
cine was still similar to the duration 
estimated in 1993–1994. This surveil-
lance was necessary because antigenic 
changes in circulating isolates of Bor-
detella pertussis were observed when 
compared with vaccine strains (7). To 
achieve this goal, a private pediatric 
network was set up and data from this 
surveillance are presented.
From September 2002 through 
April 2006, 79 pediatricians in France 
enrolled all infants and children sus-
pected of having pertussis. A stan-
dardized data form was completed for 
age, sex, vaccination data, and source 
of infection. Biologic conﬁ  rmation of 
cases was obtained by using routine 
laboratory diagnoses, i.e., culture, 
PCR, or serology. Real-time PCR was 
performed according to consensus 
rules (8). Routine serodiagnosis was 
performed by using puriﬁ  ed pertussis 
toxin and Western blotting according 
to the method of Guiso et al. (9) be-
cause this is the only diagnostic test 
free for patients in France. Serologic 
diagnosis was made by detecting an-
tibodies to pertussis toxin in unvacci-
nated children or in those vaccinated 
>1 year earlier. Epidemiologic case-
patients were deﬁ  ned as those with a 
cough for 14 days who had contacts 
with a conﬁ  rmed case-patient within 4 
weeks of the onset of the cough. No 
conﬁ  rmed suspected case-patients had 
coughs; all were negative for pertus-
sis by biologic diagnosis and did not 
report contact with a conﬁ  rmed case-
patient.
A total of 383 children were en-
rolled in the study. However, vaccina-
tion status and a biologic diagnosis 
were available for only 139 children 
(Table). Forty-seven children had bio-
logically conﬁ  rmed cases and 92 had 
nonconﬁ  rmed cases. Among children 
with conﬁ   rmed cases, only 22 had 
been vaccinated. At time of disease, 
the mean ± SD age of these children 
was 9.9 ± 2.1 years. This age was 
similar to the age observed during 
1993–1994 (1,5).
The diagnosis for the 92 children 
suspected of having pertussis was not 
conﬁ   rmed biologically. Culture and 
PCR are used for diagnosis early in 
the course of pertussis. However, se-
rologic analysis is used later because 
antibodies are rarely detected before 
3 weeks of onset of a cough. More 
culture and PCR diagnoses were per-
formed for unvaccinated conﬁ  rmed 
case-patients than for vaccinated 
conﬁ  rmed case-patients. This ﬁ  nding 
suggests that unvaccinated children 
were seen by their pediatricians ear-
lier than vaccinated children because 
the disease was less severe in vacci-
nated children or that vaccinated chil-
dren were older than unvaccinated 
children.
The source of contamination 
was known for 47% of the conﬁ  rmed 
case-patients (Table). This source was 
either adults (54.4%) or adolescents 
(41%) who did not receive their sec-
ond booster immunization or an un-
vaccinated infant (4.5%). These data 
are similar to those obtained by the 
French hospital-based surveillance 
(2). They also support the strategy 
started in 2004 of recommending a 
pertussis booster immunization for 
adults in contact with children and all 
healthcare workers who come in con-
tact with infants (10)
In conclusion, this pediatric sur-
veillance conﬁ   rms the usefulness of 
following vaccine recommendations 
for pertussis and of using biologic 
techniques to conﬁ   rm a diagnosis. 
The vaccine strategy recommending a 
booster vaccination at 11–13 years of 
age is still in accordance with epide-
miologic features observed. Pediatri-
cians should continue this surveillance 
to evaluate evolution of B. pertussis 
populations and the effect of replacing 
Pw vaccines with Pa vaccines.
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Table. Characteristics of confirmed and nonconfirmed pertussis case-patients for whom vaccination status with pertussis whole-cell
(Pw) vaccine was known 
Vaccinated 4× with Pw vaccine (N = 70)  Unvaccinated (N = 69) 
Characteristic
Confirmed
case-patients (n = 22) 
Nonconfirmed
case-patients (n = 48) 
Confirmed
case-patients (n = 25) 
Nonconfirmed
case-patients (n = 44) 
Diagnostic method 
 Culture  0† 3*
 PCR  7† 17*
 Serology  13 3
 Epidemiology  2 2
Age, y  9.9 ± 2.1†  7.8 ± 3.4  2.3 ± 3.9†  0.8 ± 2.3 
p value for age  0.008 0.0046
Source of contamination 
 Adults  5 7
 Adolescents  4 5
 Infants  1  (unvaccinated)  0
*p = 0.0009 for PCR and culture for case-patients receiving 4 doses of Pw vaccine versus unvaccinated confirmed case-patients. 
†p<0.0001 by age for case-patients receiving 4 doses of Pw vaccine versus unvaccinated confirmed case-patients. LETTERS
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Avian Mycoplasma 
lipofaciens 
Transmission to 
Veterinarian
To the Editor: Mycoplasma spp. 
are well-known pathogens in human 
and veterinary medicine. Mammals, 
especially primates and including hu-
mans, share similar or even identical 
Mycoplasma spp., which might be 
commensal or pathogenic (1). Ad-
ditionally, sporadic infections of im-
munocompromised persons with My-
coplasma spp. that originated from 
domestic animals have been reported 
(1); susceptibility in this human popu-
lation is increased (2,3). M. phocicere-
brale is the only Mycoplasma patho-
gen of animals that regularly infects 
humans, causing a disease called seal 
ﬁ  ngers  (1,4). However, we report a 
human infection with an avian Myco-
plasma organism.
A clinical trial to investigate the 
capability of M. lipofaciens (strain 
ML64) (5) to spread horizontally be-
tween infected and noninfected turkey 
poults in an incubator demonstrated 
airborne transmission of the patho-
gen within 24 hours (6). During the 
trial, the veterinarian conducting the 
study, a 36-year-old man, was moni-
tored for infection. Each day, 2 swabs 
were taken from both nostrils, starting 
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